Evotec and Related Sciences extended their partnership through 2030 to more than 15 programs.
Related Sciences' Facets opportunity selection engine is paired with Evotec's drug discovery platform and AI/ML capabilities, and the work now adds covalent inhibitor discovery. The page cites over 15 multi-modality programs since the early-2021 launch. Evotec is eligible for milestones, royalties and a founding equity stake in assets.
Evotec is a drug discovery and development services company that pairs AI partners with its integrated R&D platform in oncology and immunology.
This sits in the Design & Stress-Test stage of the AI use-case lifecycle: Named examples from the tools pharma teams use to scope, prototype and benchmark an AI use case before committing to build it — data-catalog, sandbox and evaluation platforms.
Published by Evotec on its own site — read the original case study on evotec.com ↗
Related use cases
- 01Evotec and Owkin combined AI target discovery with Evotec's R&D platform in oncology and immunology.
- 02Celgene, Evotec's partner Exscientia and Evotec began a three-year AI drug discovery collaboration in oncology and autoimmunity.
- 03Novo Nordisk Transforms Clinical Trials With AI
- 04How Regeneron is discovering new treatments with AI
- 05How AI is changing drug discovery
- 06Bayer transforms global data management with Databricks